Insight, China's Pharmaceutical Industry

Shyndec Pharmaceutical

  • Shyndec’s Generic Cytosar-U Gains Marketing Approval in China

    •

    Fineline Cube

    China-based Shanghai Shyndec Pharmaceutical Co., Ltd (SHA: 600420) has announced that its generic version of Pfizer’s (NYSE: PFE) Cytosar-U (cytarabine) has obtained marketing approval in China. This marks the first generic to pass the generic quality consistency evaluation among similar products in the country. Product Profile and Market ContextCytarabine for…

Fineline Info & Tech